3,557 results on '"Medullary thyroid cancer"'
Search Results
2. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
3. A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121)
4. Predictive Factors for Medullary Thyroid Cancer Aggressiveness (MYELO)
5. A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)
6. A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)
7. 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
8. Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma? (DSR-MTC)
9. A Study of TY-1091 in Patients With Advanced Solid Tumors
10. Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
11. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
12. A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC)
13. The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare Tumor Registry Accurately Represent the Real-World Patient Population?
14. Pre-Operative Calcitonin and CEA Values May Predict the Extent of Metastases to the Lateral Neck Lymph Nodes in Patients with Medullary Thyroid Cancer.
15. Diagnostic Performance of Preoperative Calcitonin and Procalcitonin Tests for Differential Diagnosis of Medullary Thyroid Cancer.
16. The impact of preoperative calcitonin screening on the prognosis of patients with medullary thyroid cancer: a retrospective multicenter cohort study.
17. Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment.
18. Oncological Outcome and Treatment Options of Medullary Thyroid Cancers: Experience at a Tertiary Cancer Centre.
19. RET 634 germline/gonadal mosaicism generating a second pathogenic amino acid change in multiple endocrine neoplasia type 2A.
20. Physiological and therapeutic role of calcitonin
21. Central Neck Dissection
22. Suspected Malignancy and Malignant Thyroid Tumors
23. Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
24. A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
25. Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
26. Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)
27. Well-defined survival outcome disparity across age cutoffs at 45 and 60 for medullary thyroid carcinoma: a long-term retrospective cohort study of 3601 patients.
28. Medullary Thyroid Cancer: Epidemiology and Characteristics According to Data From the Marne-Ardennes Register 1975-2018.
29. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review.
30. Immunotherapy for endocrine tumours: a clinician's perspective.
31. Efficacy and safety of pralsetinib in Chinese advanced A£7-mutant medullary thyroid cancer patients.
32. Is Thyroid Stimulating-Hormone related to Functional Tumor Burden in Patients with Advanced Medullary Thyroid Cancer?
33. Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
34. A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)
35. Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature
36. Real-world clinical profile, RET mutation testing, treatments and patient-related outcomes for medullary thyroid cancer in Europe
37. Kinase inhibitors in thyroid cancers
38. Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
39. Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
40. RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report.
41. Latest Progress in Risk-Adapted Surgery for Medullary Thyroid Cancer.
42. An old friend, a new insight: Calcitonin measurement in serum and aspiration needle washout fluids significantly increases the early and accurate detection of medullary thyroid cancer.
43. Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer.
44. Impact of Early Diagnostic and Therapeutic Interventions and Clinical Course in Children and Adolescents with Multiple Endocrine Neoplasia Types 1 and 2.
45. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
46. A Proposed Modified Staging System for Medullary Thyroid Cancer: A SEER Analysis With Multicenter Validation.
47. Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier
48. Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review
49. Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
50. Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.